Jason Sheltzer thought he was learning answers to a simple question, but one that, for cancer patients, could mean the difference between life and death: Which genes can’t tumor cells survive without? Identifying DNA that seems essential to cancer cells’ survival tells drug developers which genes or gene products to target — a tried-and-true approach that has led to such lifesaving cancer drugs as Herceptin.

But the research took an unexpected turn. Working with human cancer cells growing in a dish, Sheltzer, a biologist at Cold Spring Harbor Laboratory, and his colleagues used CRISPR genome editing to knock out DNA that more than 180 previous studies had identified as essential in various forms of cancer. Those studies concluded that the tumors can’t survive without the proteins made by these genes. But in DNA-knockout after DNA-knockout, Sheltzer’s team found, the cancer cells kept on despite the lack of an “essential” protein. It was like a car from which the carburetor had been stolen speeding down the highway unfazed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy